NEUROCRINE BIOSCIENCES, INC.
πΈπͺSweden
- Country
- πΈπͺSweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 12
- Registration Number
- NCT02959892
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 155
- Registration Number
- NCT02879578
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Phase 1
Completed
- Conditions
- Healthy VolunteersSchizophrenia
- Interventions
- Drug: TAK-041 Placebo
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 114
- Registration Number
- NCT02748694
- Locations
- πΊπΈ
Parexel Early Phase Clinic Unit- Los Angeles, Glendale, California, United States
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 161
- Registration Number
- NCT02736955
Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 20
- Registration Number
- NCT02716987
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 98
- Registration Number
- NCT02679079
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 124
- Registration Number
- NCT02581865
A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants
Phase 1
Terminated
- Conditions
- Schizophrenia, Cerebellar Ataxia
- Interventions
- Drug: TAK-831 Oral SuspensionDrug: TAK-831 PlaceboDrug: TAK-831 Tablet
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 110
- Registration Number
- NCT02566759
TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 88
- Registration Number
- NCT02561156
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 167
- Registration Number
- NCT02405091
Β© Copyright 2025. All Rights Reserved by MedPath